616
Views
20
CrossRef citations to date
0
Altmetric
Drug Safety Evaluation

Rupatadine: global safety evaluation in allergic rhinitis and urticaria

, &
Pages 1439-1448 | Received 12 May 2016, Accepted 03 Aug 2016, Published online: 19 Aug 2016

References

  • Bousquet J, Van Cauwenberge P, Khaltaev N, ARIA Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(Suppl 5):S147–S334.
  • Bousquet J, Van Cauwenberge P, Khaled NA, et al. Pharmacologic and anti-IgE treatment of allergic rhinitis (ARIA) update (in collaboration with GA2LEN). Allergy. 2006;61:1086–1096.
  • Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008;63(Suppl. 86):8–160.
  • Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868–887.
  • Church MK, Máspero JF, Maurer M, et al. The scope of pharmacological and clinical effects of modern antihistamines, with a special focus on rupatadine. Wao J. 2010;3(Suppl 4):S1–S16.
  • Muñoz-Cano R, Valero A, Roca-Ferrer J, et al. Platelet-activating factor nasal challenge induces nasal congestion and reduces nasal volume in both healthy volunteers and allergic rhinitis patients. Am J Rhinol Allergy. 2013;27:e48–52.
  • Muñoz-Cano R, Valero A, Izquierdo I, et al. Evaluation of nasal symptoms induced by platelet activating factor, after nasal challenge in both healthy and allergic rhinitis subjects pretreated with rupatadine, levocetirizine or placebo in a cross-over design. Allergy Asthma Clin Immunol. 2013;9:43.
  • Church MK, Maurer M, Simons FER, et al. Risk of first-generation H1-antihistamines: a GA2LEN position paper. Allergy. 2010;65:459–466.
  • Simons FER, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011;128:1139–1150.
  • Brożek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. J Allergy Clin Immunol. 2010;126:s466-476.
  • Mullol J. Positioning of antihistamines in the allergic rhinitis and its impact on asthma (ARIA) guidelines. Clin Exper Allergy Rev. 2012;12:17–26.
  • Mullol J, Bousquet J, Bachert C, et al. Update on rupatadine in the management of allergic disorders. Allergy. 2015;70:1–24.
  • Nettis E, Delle Donne P, Di Leo E, et al. Rupatadine for the treatment of urticaria. Expert Opin Pharmacother. 2013;14:1807–1813.
  • Merlos M, Giral M, Balsa D, et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther. 1997;280:114–121.
  • Merlos M, Balsa D, Giral M, et al. Inhibition of rat peritoneal mast cell exocytosis by rupatadine fumarate: a study with different secretagogues. Methods Find Exp Clin Pharmacol. 1997;19(Suppl.A):148.
  • Van Den Anker-Rakhmanina NY. Rupatadine. Curr Opin Antiinflamm Immumomodul Invest Drugs. 2000;2:127–132.
  • Izquierdo I, Merlos M, Garcia-Rafanell J. Rupatadine, a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist: a review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today (Barc). 2003;39:451–468.
  • Giral M, Balsa D, Ferrando R, et al. CNS activity profile of rupatadine fumarate, a new dual receptor antagonist of platelet-activating factor (PAF) and histamine. Allergy. 1998;53(Suppl.):131.
  • Merlos M, Ferrando R, Giral M, et al. Effect of topical rupatadine in experimental conjunctivitis in guinea pigs: macroscopic evaluation of ocular lesions. J Allergy Clin Lmmunol. 2001;107(Suppl. 2):S310.
  • Queralt M, Merlos M, Giral M, et al. Dual effect of a new compound, rupatadine, on edema induced by platelet-activating factor and histamine in dogs: comparison with antihistamines and PAF antagonists. Drug Dev Res. 1996;39:12–18.
  • Queralt M, Brazis P, Merlos M, et al. lnhibitory effects of rupatadine on mast cell histamine release and skin wheal development induced by Ascaris suum in hypersensitive dogs. Drug Dev Res. 1998;44:49–55.
  • Queralt M, Brazis P, Merlos M, et al. In vitro inhibitory effect of rupatadine on histamine and TNF-α release from dispersed canine skin mast cells and the human mast cell line HMC-I. Lnflamm Res. 2000;49:355–360.
  • Ferrando R, Giral M, Balsa D, et al. Protective effect of rupatadine fumarate in experimental conjunctivitis in Guinea pigs. Methods Find Exp Clin Pharmacol. 1996;18(Suppl.B):140.
  • Ferrando R, Giral M, Balsa D, et al. Protective effect of rupatadine fumarate in experimental conjunctivitis in Guinea pigs. Methods Find Exp Clin Pharmacol. 1996;18(Suppl.B):140.
  • Mullol J, Bousquet J, Bachert C, et al. Rupatadine in allergic rhinitis and chronic urticaria. Allergy. 2008;63(Suppl 87):5–28.
  • Barrón S, Ramis I, Merlos M. Rupatadine inhibits the inflammatory component of allergic response: cytokine release, adhesion molecule expression and inflammatory cell recruitment. 23rd EAACI Congress, 12–16 June 2004, Amsterdam.
  • Merlos M, Ramis I, Balsa D, et al. Inhibitory effect of rupatadine on TNF-α release from human monocytes and mast cell line HMC-1. J Allergy Clin Lmmunol. 2000;105(Suppl. 1):S62.
  • Merlos M, Giral M, Balsa D, et al. Rupatadine inhibits the eosinophil recruitment in BAL fluid of ovalbumin-sensitized Guinea pigs. J Allergy Clin Lmmunol. 1998;101(Suppl. 1):S218.
  • Izquierdo I, Nieto C, Ramis J, et al. Pharmacokinetics and dose linearity of rupatadine fumarate in healthy volunteers. Methods Find Exp Clin Pharmacol. 1997;19(Suppl.A):189–203.
  • Barrón S, Roman J, Michelena P, et al. Rupatadine inhibits cytokine production and NF-kB activity by histamine H1 receptor-dependent mechanism. Rev Rinol. 2006;6:18.
  • Barrón S, Ramis I, Merlos M. Effect of rupatadine on lymphocyte cytokine production. Allergy Clin Immunol Int. 2005;1(Suppl. 1):427.
  • Curtin ML. Current status of platelet-activating factor antagonists. Exp Opin Ther Patents. 1998;8:703–711.
  • Vasiadi M, Kalogeromitros D, Kempuraj D, et al. Rupatadine inhibits proinflammatory mediator secretion from human mast cells triggered by different stimuli. Int Arch Allergy Immunol. 2010;151:38–45.
  • Ramis I, Giral M, Ferrando R, et al. Inhibition of PAF- and LTB4-induced human neutrophil chemotaxis by rupatadine using a new fluorescent chemotaxis assay. Allergy. 2000;55(Suppl. 63):94–95.
  • Alevizos M, Karagkouni A, Vasiadi M, et al. Rupatadine inhibits inflammatory mediator release from human laboratory of allergic diseases 2 cultured mast cells stimulated by platelet-activating factor. Ann Allergy Asthma Immunol. 2013;111:542–547.
  • Muñoz-Cano R, Torres Atencio I, Ainsua E, et al. Effects of rupatadine on platelet activating factor (PAF) induced human mast cell degranulation compared with desloratadine and levocetirizine. J Allergy Clin Immunol. 2012;129(Suppl 2):AB122.
  • Muñoz-Cano R, Ainsua-Enrich E, Torres-Atencio I, et al. Effects of rupatadine on Platelet activating factor (PAF)-induced human mast cell degranulation compared with desloratadine and levocetirizine (The MASPAF study). J Investig Allergol Clin Immunol. Forthcoming 2016.
  • Church MK. Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males. Br J Dermatol. 2010;163:1330–1332.
  • Scannell RT, Differding E, Talaga P. Dual acting antihistaminergic agents. Mini Rev Med Chem. 2004;4:923–933.
  • Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother. 2006;7:1989–2001.
  • Katiyar S, Prakash S. Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis. Prim Care Respir J. 2008;18:57–68.
  • Keam SJ, Plosker GL. Rupatadine: a review of its use in the management of allergic disorders. Drugs. 2007;67:457–474.
  • Summary of product characteristics (SPC). Rupafin 10mg tablets; [cited2016 Apr]. Available from: http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA1129-001-001_22042015104040.pdf.
  • Summary of product characteristics. Rupafin 1mg/ml oral solution; cited 2016Mar. Available from: http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1424669527506.pdf.
  • Valle M, Estevez J, Martial LC, et al. Application of population pharmacokinetic modelling and simulation in the design of the optimal dose regime of rupatadine in 2–5 year old children. Clin Transl Allergy. 2014;4(Suppl 1):P39.
  • Solans A, Izquierdo I, Donado E, et al. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady state levels: a randomized, open-label, twoway, crossover, phase I study. Clin Ther. 2008;30:1639–1650.
  • Solans A, Carbó ML, Peña J, et al. Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study. Clin Ther. 2007;29:900–908.
  • Izquierdo I, Pareds I, Lurigados C, et al. A dose ranging study of rupatadine fumarate in patients with seasonal allergic rhinitis. Allergy. 2000;55:275.
  • Eloy P, Tobback L, Imschoot J. Rupatadine improves health related quality of life and severity of allergic rhinitis in a Belgian cohort of 2,800 patients. Allergy. 2012;67(Suppl s96):331.
  • Barbanoj MJ, García-Gea C, Morte A, et al. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology. 2004;50:311–321.
  • Shamizadeh S, Brockow K, Ring J. Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects. Allergo J Int. 2014;23(3):87–95.
  • Barbanoj MJ, Garcia-Gea C, Antonijoan R, et al. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers. Hum Psychopharmacol Clin Exp. 2006;21(1):13–26.
  • García-Gea C, Ballester MR, Martínez J, et al. Rupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double-blind, crossover, repeated dose, placebo-controlled study. Br J Clin Pharmacol. 2010;69:663–674.
  • Vuurman E, Theunissen E, Van Oers A, et al. Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers. Hum Psychopharmacol Clin Exp. 2007;22(5):289–297.
  • Maiti R, Rahman J, Jaida J, et al. Rupatadine and levocetirizine for seasonal allergic rhinitis: a comparative study of efficacy and safety. Arch Otolaryngol Head Neck Surg. 2010;136:796–800.
  • Maiti R, Jaida J, Raghavendra BN, et al. Rupatadine and levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety. J Drugs Dermatol. 2011;10:1444–1450.
  • Lu HR, Hermans AN, Gallacher DJ. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torssades de Pointes? Br J Pharmacol. 2012;166(4):1490–1502.
  • DuBuske LM. Second-generation antihistamines: the risk of ventricular arrhythmias. Clin Ther. 1999;21(2):281–295.
  • Donado E, Izquierdo I, Pérez I, et al. No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a ‘thorough QT/QTc study’ performed according to ICH guidelines. Br J Clin Pharmacol. 2010;69:401–410.
  • Potter P, Maspero JF, Vermeulen J, et al. Rupatadine oral solution in children with persistent allergic rhinitis: a randomized, double-blind, placebo- controlled study. Pediatr Allergy Immunol. 2013;24:144–150.
  • Valero A, De La Torre F, Castillo JA, et al. Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain. Drug Saf. 2009;32:33–42.
  • Caballero R, Valenzuela C, Longobardo M. Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac Kv1.5 channels. Br J Pharmacol. 1999;128:1071–1081.
  • Lukat K, Rivas P, Roger A, et al. A direct comparison of efficacy between desloratadine and rupatadine in seasonal allergic rhinoconjunctivitis: a randomized, double-blind, placebo-controlled study. J Asthma Allergy. 2013;6:31–39.
  • Potter P, Mitha E, Barkai L, et al. Rupatadine is effective in the treatment of chronics spontaneous urticaria in children aged 2–11 years. Pediatr Allergy Immunol. 2016;27:55–61.
  • Compalati E, Canonica GW. Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. Curr Med Res Opin. 2013;29:1539–1551.
  • Fantin S, Maspero J, Bisbal C, et al. A 12-week placebo-controlled study of rupatadine 10mg once daily comparative with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis. Allergy. 2008;63(7):924–931.
  • Giménez-Arnau A, Pujol RM, Ianosi S, et al. Rupatadine in the treatment of the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicenter study. Allergy. 2007;62:539–546.
  • Dubertret L, Zalupca L, Cristodoulo T, et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol. 2007;17:223–228.
  • Metz M, Scholz E, Ferrán M, et al. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol. 2010;104:86–92.
  • Abajian M, Curto-Barredo L, Krause K, et al. Rupatadine 20 mg and 40 mg are Effective in Reducing the Symptoms of Chronic Cold Urticaria. Acta Derm Venereol. 2016;96:56–59.
  • Vlastarakos PV, Manolopoulos L, Ferekidis E, et al. Treating common problems of the nose and throat in pregnancy: what is safe? Eur Arch Otorhinolaryngol. 2008;265:499–508.
  • Izquierdo I, Taubel J, Ferber G, et al. Rupatadine pharmacokinetics in Japanese healthy volunteers after single and repeated oral doses of 10, 20 and 40 mg. Wao J. 2016;9(Suppl 1):A202.
  • Simons FER. Advances in H1-antihistamines. N Engl J Med. 2004;351:2203–2217.
  • Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol. 2000;105:S622–627.
  • Bender BG, Berning S, Dudden R, et al. Sedation and performance impairment of diphenhydramine and second-generation antihistamines: a meta-analysis. J Allergy Clin Immunol. 2003;111:770–776.
  • McDonald K, Trick L, Boyle J. Sedation and antihistamines: an update. Review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol. 2008;23(7):555–570.
  • Barbey JT, Anderson M, Ciprandi G, et al. Cardiovascular safety of second-generation antihistamines. Am J Rhinology. 1999;13:235–243.
  • Phan H, Moeller ML, Nahata MC. Treatment of allergic rhinitis in infants and children. Efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. Drugs. 2009;69:2541–2576.
  • Bachert C, Kuna P, Sanquer F, et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5mg in seasonal allergic rhinitis patients. Allergy. 2009;64:158–165.
  • González-Núñez V, Valero A, Mullol J. Safety evaluation of desloratadine in allergic rhinitis. Expert Opin Drug Saf. 2013;12:445–453.
  • Saint-Martin F, Dumur JP, Pérez I, et al. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10mg), a new PAF and H1 receptor specific histamine antagonist, to loratadine 10mg in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol. 2004;14:34–40.
  • Guadaño EM, Serra-Batlles J, Meseguer J, et al. Rupatadine 10mg and ebastine 10mg in seasonal allergic rhinitis: a comparison study. Allergy. 2004;59:766–771.
  • Martinez-Cócera C, De Molina M, Marti-Guadaño E, et al. Rupatadine 10mg and cetirizine 10mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. J Lnvestigat Allergol Clin Immunol. 2005;15:22–29.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.